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Consider How to Balance
Cardiorenometabolic Beneﬁts
and Risks of Statins?We thank Dr. Koh for his thoughtful comments regarding our
paper (1). There is little doubt that statins are one of the most
effective drug classes of our generation. The mechanisms under-
lying their effectiveness continue to be studied carefully, and there
is growing recognition that their nonlipid (pleiotropic) effects (their
anti-inﬂammatory actions in particular) may impart an important
portion of the beneﬁts of statins to the atherosclerotic milieu. In
support of this concept, we recently observed that the beneﬁcial
impact of atorvastatin on atherosclerotic inﬂammation, as
measured by ﬂuorodeoxyglucose–positron emission tomography/
computed tomography imaging, was not signiﬁcantly related to the
magnitude of low-density lipoprotein reduction (1). Furthermore, a
growing number of studies have highlighted anti-inﬂammatory
beneﬁts of statins that extend beyond atherosclerotic diseases,
including the example raised by Dr. Koh, wherein high-dose
atorvastatin was found to reduce periodontal inﬂammation (2).
Such observations may ultimately pave the way for even broader use
of statins, pending conﬁrmation in clinical endpoint trials. More-
over, the recently published Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults makes recommendations for statin dosing based more on
risk assessment than on lipid targets (3) and is predicted to increase
the number of Americans who will be treated with statins (4).
Accordingly, the point raised by Dr. Koh is both important and
timely: as we continue to expand the use of statins and contemplate
new indications for them, we should in parallel continue to carefully
study the mechanisms underlying their negative effects, especially
in higher doses. It is hoped that a better understanding of the
mechanisms underlying both the beneﬁts and the untoward effects
of statins will ultimately contribute to the development of novel,
more effective therapies.*Ahmed Tawakol, MD
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of Sickle Cell Disease
Beyond Classiﬁcation Constraints
We read with interest the “Updated Clinical Classiﬁcation of Pul-
monaryHypertension” by Simonneau et al. (1) in a recent issue of the
Journal. We are concerned that although systemic sclerosis, portal
hypertension, schistosomiasis, and chronic hemolysis result in pul-
monary hypertension (PH) that spans several diagnostic groups, the
rules for subgroup inclusion into Group I have not been consistently
applied. On behalf of the American Thoracic Society–sponsored
Clinical Guidelines for the Diagnosis and Treatment of Pulmonary
Hypertension in Sickle Cell Disease Committee (2), we would like to
clarify several points. PH associated with chronic hemolysis has been
moved to Group V in the 2013 classiﬁcation based on: 1) different
histopathology and lower pulmonary vascular resistance (PVR)
compared with other pulmonary arterial hypertension (PAH) sub-
groups; and 2) no proven response to PAH-speciﬁc medications.
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2882Although we agree that sickle cell disease–PH is multifactorial, the
hemodynamics of pre-capillary PH in SCD need to be clariﬁed. We
have deﬁned pre-capillary SCD-PH similar to other PAH sub-
groups: mean pulmonary arterial pressure 25 mm Hg with mean
pulmonary capillary wedge pressure or left ventricular end-diastolic
pressure 15 mm Hg, plus increased PVR. However, what consti-
tutes increased PVR in SCD differs from other PAH subgroups.
Anemia-induced elevation of cardiac output and reduction in blood
viscosity results in a lower pre-morbid PVR (3). In idiopathic PAH,
increased PVR is deﬁned as 240 dynes$s$cm–5, 2 SDs above the
pre-morbid PVR of80 to 120 dynes$s$cm–5. Three hemodynamic
studies (4–6) have demonstrated that SCD adults without PH had a
mean cardiac output of 8 to 9 l/min with a PVR of 72 to 74  25
to 38 dynes$s$cm–5. In the absence of a consensus deﬁnition
of elevated PVR in SCD, experts consider values that are 2 to 3 SDs
above normal (i.e., 160 dynes$s$cm–5) to be signiﬁcant.
We agree that the literature evaluating PAH therapy in SCD-
PH is limited. However, we also believe that the 3 clinical trials
conducted in these patients are insufﬁcient to determine whether
SCD patients with pre-capillary PH should receive PAH therapy.
These trials collectively enrolled only 14 patients with pre-capillary
PH (fewer than one-half of whom received vasodilators), resulting
in imprecisely estimated effects (7,8). There are 4 case series in
which SCD patients with pre-capillary PH were treated with
bosentan, sildenaﬁl, and/or epoprostenol. Vasodilator therapy led
to an increase in 6-min walk distance 41 to 144 m above baseline
(9–11), with improvements in mean pulmonary arterial pressure,
PVR, and cardiac index (11). On the basis of these studies com-
bined with our clinical experience, we weakly recommended a trial
of either an endothelin receptor antagonist or a prostacyclin analog
for select SCD patients with symptomatic pre-capillary PH. We
are concerned that the 2013 classiﬁcation will limit access for these
patients to clinically beneﬁcial PAH-speciﬁc medications.
The reclassiﬁcation of SCD-PH as Group IV, Group I, and now
as Group V reﬂects the imprecise nature of the classiﬁcation. It
stresses the need to deﬁne PH subgroups so that all patients may
beneﬁt from the available treatment options.*Elizabeth S. Klings, MD
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Sickle Cell Disease Beyond
Classiﬁcation Constraints
The Second World Symposium on Pulmonary Hypertension, held
in Evian, France, in 1998, settled the basis of the current classiﬁ-
cation system, representing a signiﬁcant step forward as compared
to the previous approach that separated pulmonary hypertension
(PH) into primary or secondary forms (1).
Since then, PH has been classiﬁed into 5 different categories
trying to group together patients sharing similar hemodynamic
proﬁle, pathological ﬁndings, and therapeutic approach/response.
Hemolytic anemia as an associated condition to the develop-
ment of pre-capillary PH has been changed into group 5 not just
because of the hemodynamic proﬁle. Indeed, recent cohorts on PH
associated to hemolytic anemias demonstrated a singular hemo-
dynamic proﬁle, as a consequence of high cardiac output, with
elevated pulmonary pressures and low pulmonary vascular resis-
tance (2–4). This fact was markedly relevant to support the deci-
sion of not including pulmonary vascular resistance as a mandatory
part of the deﬁnition of PH, since different cardiac output states
would demand different cutoffs of abnormality. Even more
importantly, the available data on the pathological ﬁndings and
treatment trials for patients with PH associated to hemolytic
anemia have also been reviewed. As mentioned by Klings et al. (2),
literature evaluating pulmonary arterial hypertension (PAH)
therapy in sickle cell disease associated PH is limited. In fact, there
is no consistent controlled data supporting the use of speciﬁc PAH
therapy in this setting. Regarding pathology ﬁndings, differently
from all other subforms of PAH included in group 1, many in-
consistencies also exist regarding the pulmonary vascular ﬁndings
in patients with sickle cell disease and PH. In the study from
Haque et al. (5), 1 of the largest available series, most of the
